Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring
CTNNB1
HCC
Liquid biopsy
atezolizumab plus bevacizumab
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
01
2022
accepted:
08
05
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Atezolizumab plus bevacizumab (ATZ/BV) treatment is a combined immunotherapy consisting of immune checkpoint inhibitor (ICI) and anti-vascular endothelial growth factor monoclonal antibody, which has brought a major paradigm shift in the treatment of unresectable hepatocellular carcinoma (HCC). Gain-of-function mutation of
Identifiants
pubmed: 35711837
doi: 10.7150/jca.71494
pii: jcav13p2656
pmc: PMC9174847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2656-2661Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: Tetsuhiro Chiba and Tatsuo Kanda received grant support from Chugai Pharmaceuticals Ltd. Sadahisa Ogasawara received honoraria from Chugai Pharmaceuticals Ltd. Naoya Kato received grant support, advisory fee, and honoraria from Chugai Pharmaceuticals Ltd. All the other authors have no conflicts of interest to declare.
Références
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):340-9
pubmed: 24473361
Nat Med. 2019 Sep;25(9):1415-1421
pubmed: 31501609
Cancer Res. 2009 Sep 15;69(18):7385-92
pubmed: 19723656
Clin Cancer Res. 2019 May 15;25(10):3074-3083
pubmed: 30635339
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
Genes Cancer. 2011 Dec;2(12):1097-105
pubmed: 22866201
Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124
pubmed: 29229461
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Cancer Res. 2021 Feb 15;81(4):1052-1062
pubmed: 33408116
Pancreatology. 2021 Apr 15;:
pubmed: 33865724
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Cancer. 1987 Aug 15;60(4):810-9
pubmed: 2439190
Cancer Cell. 2017 Feb 13;31(2):172-179
pubmed: 28196593
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Eur J Cancer. 2016 Jul;62:138-45
pubmed: 27237360
Genomics. 2013 Aug;102(2):74-83
pubmed: 23583669
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
J Hematol Oncol. 2017 May 5;10(1):101
pubmed: 28476164
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
J Hematol Oncol. 2019 Sep 5;12(1):92
pubmed: 31488176
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
Gastroenterology. 2017 Sep;153(3):812-826
pubmed: 28624577
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):139-152
pubmed: 31792430
Infect Agent Cancer. 2020 Jun 3;15:37
pubmed: 32514293
Nat Med. 1996 Oct;2(10):1096-103
pubmed: 8837607
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302